* Biora AB, of Malmo, Sweden, said it received marketing approval in Japan for Emdogain for periodontal disease. Biora has negotiated an alliance with Seikagaku Corp., of Japan, for selling the drug in that country.
* Elan Corp. plc, of Athlone, Ireland, completed its agreement with Endorex Corp., of Chicago, establishing a joint venture for the development and commercialization of oral and mucosal vaccines. The deal was disclosed in early January and the new entity is expected to be named shortly. (See BioWorld International, Jan. 14, 1998, p. 1.)